The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and 
dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant 
melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is 
known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports 
in patients with progressive, radioactive iodine-refractory BRAF-mutant 
papillary thyroid cancer suggest response rates of approximately 30-40%. In this 
review, we discuss BRAF inhibitors in the context of thyroid cancer, the 
toxicities associated with BRAF inhibitors, and the suggested management of 
those toxicities. The management of vemurafenib and dabrafenib toxicities is 
applicable across all tumor types and may serve as a practical guide to their 
use.